Autologous DC - CTL/TIL for breast cancer prevention and its safety and efficacy of treatment

Autologous DCS - CTL/TIL for breast cancer prevention and its safety and efficacy of treatment

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17011292

Enrollment

Unknown

Registered

2017-05-04

Start date

2017-07-01

Completion date

Unknown

Last updated

2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Observation group:DC/CTL/TIL

control group:nun

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Consent to participate in clinical trials; 2. Aged 18 to 60 years; 3. Having full capacity for civil conduct.

Exclusion criteria

Exclusion criteria: 1. Severe cerebrovascular disease, which is expected to survive less than six months; 2. Having an autoimmune disease; 3. Have virus infectious diseases (HIV, HBV, HCV, etc.); 4. Allergy to drugs; 5. Pregnancy or brain metastasis.

Design outcomes

Primary

Measure	Time frame
The incidence of BC;PFS;	—

Countries

China

Contacts

Public ContactLiang Xiao

The department of oncology of Shenzhen Second People's Hospital

wuwei_07@hotmail.com+86 13554764527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026